Cannabis and Mood: What the Evidence Actually Shows

Last updated on August 4, 2026 · Originally published November 25, 2021

Everybody knows cannabis can make you giggle. It can make music sound better, an ordinary conversation feel profound, and a bad joke seem briefly brilliant.

It can also make your heart race, your thoughts loop, and the room feel less friendly than it did five minutes ago.

Both experiences belong to the same plant. Cannabis is used widely for anxiety, depression and stress, yet anxiety is also one of its most familiar adverse effects. Whether it lifts a mood or unsettles one depends on what was taken, how much, how it was taken, and who took it.

Terpenes are often offered as part of the explanation. Limonene is said to brighten the mood, linalool to calm it, pinene to keep the mind clear. The question is how much of that comes from evidence, and how much from turning aromas into personalities.

“Cannabis” is not one thing

It is worth pausing on the word, because it conceals a great deal.

The evidence discussed below ranges from self-reported sessions with commercial flower, to controlled experiments using vaporized THC and one isolated terpene, to trials of purified cannabinoids, multi-ingredient CBD formulations, and lavender-oil capsules containing no cannabis at all.

Those are not variations on a theme. THC and CBD have importantly different anxiety profiles. Acute THC commonly increases anxiety, particularly at higher doses, though response varies with dose, experience and setting. CBD does not usually produce that response, but the evidence that it reliably treats anxiety in people remains mixed.

Route matters too, changing onset, intensity and duration substantially. Inhaled products act within minutes; oral products generally arrive later and last longer.

So when a study reports that cannabis helped or did not, the first question is which cannabis, in what form, at what dose. A good deal of the apparent disagreement in this literature is not disagreement at all. It is different substances sharing a name.

THC decides how much. The question is what kind

Start with the part nobody disputes. If your mood shifts after using cannabis, THC is overwhelmingly the reason. It is the compound behind the euphoria and the compound behind the racing heart, and nothing else in the plant comes close in effect size.

But that leaves the question the opening of this article actually poses. The giggling and the looping thoughts are both THC. So what decides which one you get?

There is a popular way of putting this. THC is the gas pedal: without it you are not going anywhere, and how hard you press determines the power. Terpenes are the steering wheel, deciding which direction all that power takes you.

It is a good analogy, and most of this article is about whether the second half of it is true.

Some of the answer is unglamorous and has nothing to do with chemistry. Dose, tolerance, setting, and whatever mood you brought with you. A large dose in an unfamiliar place will unsettle almost anyone, and no terpene profile is going to rescue it.

The interesting claim is that terpenes account for some of the remainder — that the same amount of THC feels different depending on what else is in the material. Limonene is said to make it brighter, linalool softer, pinene clearer. That is the version of the entourage hypothesis worth taking seriously, and it is the one Russo proposed in 2011: not that terpenes treat anything, but that they shape the character of a cannabinoid experience.

The question is whether they are the steering wheel or the paint job.

The clinical evidence is thinner than the mechanism

Cannabinoids have generated a great deal of animal and laboratory evidence in anxiety and mood research. The human evidence is much less convincing.

A 2021 systematic review could identify only eight very small clinical studies of CBD or THC for affective disorders, anxiety disorders or PTSD, and concluded the evidence was insufficient to recommend medical cannabis for those conditions. The literature has grown since, but not enough to establish cannabis as an effective treatment. Of the major cannabinoids, CBD remains the more plausible candidate for anxiety, though doses, formulations and results have varied considerably between studies.

For depression and bipolar disorder specifically, there remains very little controlled human evidence that cannabis or cannabinoids work as treatments. Most of what gets cited is preclinical. That is worth stating plainly, because the rest of this article concentrates on anxiety — not because anxiety matters more, but because it is where something has actually been measured.

Real-world data adds a different kind of signal. An analysis of 19,910 self-recorded sessions from 3,341 medical cannabis users found that higher labelled THC was associated with greater reported symptom relief overall, along with more side effects of both kinds. Labelled CBD potency was generally unrelated to symptom change. Within the anxiety subgroup, though, higher THC potency did not predict greater relief; the potency association was clearest for depression. This was self-selected app data rather than a controlled trial, several of its authors worked for the company behind the app, and it measured immediate self-reported experience rather than clinical efficacy or lasting improvement.

Where terpenes come in

So: does the same dose of THC feel different depending on the terpenes alongside it? That is the entourage hypothesis in its useful form, and it has been tested more than most people realise.

The best-known direct receptor and channel tests have come back negative. Research examining whether common cannabis terpenes alter THC’s activity at CB1 and CB2 receptors found no modulation — the paper was titled Absence of Entourage. A companion study of TRPA1 and TRPV1 channels found the same. Neither rules out other mechanisms, and some terpenes act at receptors directly rather than by modifying THC. But the simplest version of the story has not held up.

Two human results are worth knowing, and together they show why broad entourage claims are premature.

In a small crossover study, 20 healthy adults inhaled THC with and without different doses of D-limonene. Anxiety ratings generally declined as the limonene dose rose, but the statistically significant reductions in “anxious/nervous” and “paranoid” ratings came from the highest combination — 30 mg THC with 15 mg D-limonene — a condition only 12 participants completed, and one that was always administered last rather than fully randomised. The result is genuinely interesting and it needs replication.

Note also what it does not show. It does not show that limonene treats anxiety. It shows that a large dose of isolated limonene may blunt anxiety produced by a large dose of THC. That is a narrower claim, and arguably a more useful one.

The same group then tested α-pinene with THC in 19 adults, at 0.5, 5 and 15 mg. It found no protection against THC-related memory impairment and no meaningful change in the other acute effects measured.

One preliminary positive. One null.

The lavender problem

This is where a great deal of cannabis writing goes wrong, including two earlier versions of this article.

Lavender oil has real evidence behind it. A 539-person trial in generalized anxiety disorder found that two doses of a standardized oral lavender preparation, Silexan, reduced anxiety more than placebo. Paroxetine did not significantly beat placebo in the trial’s primary full analysis — but the study was not designed to establish that lavender was superior to paroxetine, and those comparisons were descriptive rather than prespecified. The trial was funded by the Silexan manufacturer, whose employees were among the authors.

Even taken at its best, that evidence does not transfer to cannabis, and the reason matters.

Lavender oil is a mixture in which linalool sits alongside linalyl acetate and the preparation’s other constituents. A trial of lavender oil is a trial of that combination. It is evidence that lavender oil does something. It is not evidence that linalool did it.

The doses do not correspond either. Lavender-oil trials work in tens of milligrams daily; cannabis carries linalool at fractions of a percent. A 2025 randomized trial illustrates the gap well. It tested 300 mg of CBD with one milligram each of eight terpenes, linalool included, in people with insomnia. Among the 56 participants included in the principal sleep-stage analysis, the formulation produced a small but statistically significant increase in combined slow-wave and REM sleep. Nine active ingredients, one of them linalool at a three-hundredth of the CBD dose. Whatever that trial demonstrates, it cannot tell you what the linalool contributed.

What Russo actually proposed

Ethan Russo’s Taming THC paper is the most-cited source in this area and among the most misread. He proposed that limonene, pinene and linalool might offer mood benefits, and that terpenes could moderate some of THC’s less pleasant effects — the taming in the title.

That is a hypothesis about modulation, and a reasonable one. The limonene experiment offers the clearest controlled human support so far for one narrow version of it, though its small sample and highest-dose design leave the finding provisional.

It is not, and was never presented as, a claim that terpene-rich cannabis treats depression.

Where this leaves it

There is a plausible case that terpenes shape the character of a cannabis experience, and one small human trial supporting a specific version of it. There is much weaker support for cannabis or its terpenes treating mood disorders as such, and real evidence that cannabis worsens anxiety for a meaningful number of people.

Which leaves the steering wheel unresolved. For predicting how a product will affect anxiety, cannabinoid ratio, route and dose still tell you far more than a terpene report does. Terpenes may well account for some of what is left over — the limonene result suggests they can, at least once, under controlled conditions, at a dose no cultivar delivers. Nobody has yet shown how much of the steering they actually do.

The chemistry is genuinely interesting. It is not yet advice.

For the wider context on these compounds, see our guide to cannabis terpenes.

---

Reviewed by Nani Frenkel, Chief Editor

Updated August 2, 2026. This article was substantially expanded and now incorporates material from “The Entourage Effect and Mood Disorders” by Asia Mayfield, published February 27, 2022. New sections cover product heterogeneity, the limited clinical evidence base, the human trials of limonene and pinene alongside THC, and the distinction between lavender-oil evidence and isolated linalool. The description of the Silexan trial has been corrected.

Originally published November 25, 2021

Research for this article was compiled using DeepWeed, T&T’s cannabis research database — explore the underlying studies there.

Sources

1. 1. Goldstein Ferber S, Namdar D, Hen-Shoval D, et al. The “entourage effect”: terpenes coupled with cannabinoids for the treatment of mood disorders and anxiety disorders. Curr Neuropharmacol. 2020;18(2):87–96
   2. Kedzior KK, Laeber LT. A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population — a meta-analysis of 31 studies. BMC Psychiatry. 2014;14:136. doi:10.1186/1471-244X-14-136
   3. Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties. J Transl Med. 2020;18:411. doi:10.1186/s12967-020-02518-2
   4. Stanciu CN, Brunette MF, Teja N, Budney AJ. Evidence for use of cannabinoids in mood disorders, anxiety disorders, and PTSD: a systematic review. Psychiatr Serv. 2021;72(4):429–436. doi:10.1176/appi.ps.202000189
   5. The association between cannabis product characteristics and symptom relief. Sci Rep. 2019;9:2712. doi:10.1038/s41598-019-39462-1
   6. Santiago M, Sachdev S, Arnold JC, McGregor IS, Connor M. Absence of entourage: terpenoids commonly found in Cannabis sativa do not modulate the functional activity of Δ9-THC at human CB1 and CB2 receptors. Cannabis Cannabinoid Res. 2019;4(3):165–176. doi:10.1089/can.2019.0016
   7. Heblinski M, Santiago M, Fletcher C, et al. Terpenoids commonly found in Cannabis sativa do not modulate the actions of phytocannabinoids or endocannabinoids on TRPA1 and TRPV1 channels. Cannabis Cannabinoid Res. 2020;5(4):305–317. doi:10.1089/can.2019.0099
   8. Spindle TR, Zamarripa CA, Russo E, et al. Vaporized D-limonene selectively mitigates the acute anxiogenic effects of Δ9-tetrahydrocannabinol in healthy adults who intermittently use cannabis. Drug Alcohol Depend. 2024;257:111267. doi:10.1016/j.drugalcdep.2024.111267
   9. Kumar L, Spindle TR, Zamarripa CA, Elder HJ, Russo EB, Bigelow G, Vandrey R. The individual and interactive effects of alpha-pinene and delta-9-tetrahydrocannabinol in healthy adults. Med Cannabis Cannabinoids. 2025;8(1):144–157. doi:10.1159/000547014
   10. Kasper S, Gastpar M, Müller WE, et al. Lavender oil preparation Silexan is effective in generalized anxiety disorder — a randomized, double-blind comparison to placebo and paroxetine. Int J Neuropsychopharmacol. 2014;17(6):859–869
   11. Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344–1364
   12. Wang M, Faust M, Abbott S, et al. Effects of a cannabidiol/terpene formulation on sleep in individuals with insomnia: a double-blind, placebo-controlled, randomized, crossover study. J Clin Sleep Med. 2025;21(1):69–80. doi:10.5664/jcsm.11324